Loading...
Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324
PURPOSE: Non–small-cell lung cancer (NSCLC) commonly expresses the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is a chimerized monoclonal antibody that targets the EGFR and, in preclinical models, it demonstrates radiosensitization properties. W...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Clinical Oncology
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3107747/ https://ncbi.nlm.nih.gov/pubmed/21555682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.31.7875 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|